A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader Versus Standard Endocrine Therapy Aromatase Inhibitor or Tamoxifen as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

Brief Summary

Type:
Breast Cancer

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT05952557

Study #:
STUDY00160153

Start Date:
Jul 03, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05952557

View Complete Trial Details & Eligibility at ClinicalTrials.gov